Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Wasserman

Showing results (221-230 of 259) with videos related to

Pageof 26
Sort By:
Journal of Clinical Immunology|June 22, 2016
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency DiseaseRichard L Wasserman, William Lumry, James Harris, et al.
Journal of Clinical Immunology|July 17, 2010
Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedemaTimothy J Craig, Richard L Wasserman, Robyn J Levy, et al.
Immunotherapy|September 21, 2022
Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pumpRichard L Wasserman, Charlotte Cunningham-Rundles, John Anderson, et al.
The Journal of Allergy and Clinical Immunology|August 1, 2012
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiencyRichard L Wasserman, Isaac Melamed, Mark R Stein, et al.
Journal of the Medical Library Association : JMLA|June 24, 2024
Straight to the point: evaluation of a Point of Care Information (POCI) resource in answering disease-related questionsRachel L Wasserman, Diane L Seger, Mary G Amato, et al.
Journal of Clinical Immunology|March 23, 2011
Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency diseaseRichard L Wasserman, Isaac Melamed, Lisa Kobrynski, et al.
BMJ Health & Care Informatics|May 25, 2025
Allergy alerting and overrides for opioid analogues across two health systemsRachel L Wasserman, Foster R Goss, Diane L Seger, et al.
Journal of Clinical Immunology|March 14, 2025
Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency DiseasesNiraj C Patel, Jolan E Walter, Richard L Wasserman, et al.
The American Journal of Gastroenterology|April 3, 2020
Frailty as Tested by Gait Speed Is a Risk Factor for Liver Transplant Respiratory ComplicationsTariq I Salim, Leah C Nestlerode, Erin L Lucatorto, et al.
Allergy and Asthma Proceedings|August 4, 2012
Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacksTimothy J Craig, Againdra K Bewtra, David Hurewitz, et al.
Pageof 26

Showing results (221-230 of 259) with videos related to

Sort By:
Pageof 26
Journal of Clinical Immunology|June 22, 2016
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency DiseaseRichard L Wasserman, William Lumry, James Harris, et al.
Journal of Clinical Immunology|July 17, 2010
Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedemaTimothy J Craig, Richard L Wasserman, Robyn J Levy, et al.
Immunotherapy|September 21, 2022
Systemic IgG exposure and safety in patients with primary immunodeficiency: a randomized crossover study comparing a novel investigational wearable infusor versus the Crono pumpRichard L Wasserman, Charlotte Cunningham-Rundles, John Anderson, et al.
The Journal of Allergy and Clinical Immunology|August 1, 2012
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiencyRichard L Wasserman, Isaac Melamed, Mark R Stein, et al.
Journal of the Medical Library Association : JMLA|June 24, 2024
Straight to the point: evaluation of a Point of Care Information (POCI) resource in answering disease-related questionsRachel L Wasserman, Diane L Seger, Mary G Amato, et al.
Journal of Clinical Immunology|March 23, 2011
Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency diseaseRichard L Wasserman, Isaac Melamed, Lisa Kobrynski, et al.
BMJ Health & Care Informatics|May 25, 2025
Allergy alerting and overrides for opioid analogues across two health systemsRachel L Wasserman, Foster R Goss, Diane L Seger, et al.
Journal of Clinical Immunology|March 14, 2025
Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency DiseasesNiraj C Patel, Jolan E Walter, Richard L Wasserman, et al.
The American Journal of Gastroenterology|April 3, 2020
Frailty as Tested by Gait Speed Is a Risk Factor for Liver Transplant Respiratory ComplicationsTariq I Salim, Leah C Nestlerode, Erin L Lucatorto, et al.
Allergy and Asthma Proceedings|August 4, 2012
Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacksTimothy J Craig, Againdra K Bewtra, David Hurewitz, et al.
Pageof 26